Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80(25):2361–71.

Article  PubMed  Google Scholar 

Manla Y, Almahmeed W. The pandemic of coronary heart disease in the Middle East and North Africa: what clinicians need to know. Curr Atheroscler Rep. 2023;25(9):543–57.

Article  PubMed  PubMed Central  Google Scholar 

Alsheikh-Ali AA, Omar MI, Raal FJ, et al. Cardiovascular risk factor burden in Africa and the Middle East: the Africa Middle East Cardiovascular Epidemiological (ACE) study. PLoS ONE. 2014;9(8): e102830.

Article  PubMed  PubMed Central  Google Scholar 

World Health Organization. Global report on hypertension: the race against a silent killer. 2023. Available from: https://www.who.int/publications/i/item/9789240081062. Accessed Apr 15, 2024.

Kargar S, Ansari H. Prevalence of dyslipidemias in the Middle East region: a systematic review & meta-analysis study. Diabetes Metab Syndr. 2023;17(11): 102870.

Article  CAS  PubMed  Google Scholar 

El-Kebbi IM, Bidikian NH, Hneiny L, Nasrallah MP. Epidemiology of type 2 diabetes in the Middle East and North Africa: challenges and call for action. World J Diabetes. 2021;12(9):1401–25.

Article  PubMed  PubMed Central  Google Scholar 

Hassanein M, Sabbour H, Al Awadi F, et al. Cardiometabolic guidelines: cardiovascular risk assessment and management in patients with dysglycemia. Dubai Diabetes Endocrinol J. 2023;29(2):67–88.

Article  Google Scholar 

Mahmoud I, Sulaiman N. Dyslipidaemia prevalence and associated risk factors in the United Arab Emirates: a population-based study. BMJ Open. 2019;9(11): e031969.

Article  PubMed  PubMed Central  Google Scholar 

Mezhal F, Oulhaj A, Abdulle A, et al. High prevalence of cardiometabolic risk factors amongst young adults in the United Arab Emirates: the UAE Healthy Future Study. BMC Cardiovasc Disord. 2023;23(1):137.

Article  PubMed  PubMed Central  Google Scholar 

Radaideh G, Tzemos N, Ali T, Eldershaby Y, Joury J, Abreu P. Cardiovascular risk factor burden in the United Arab Emirates (UAE): the Africa Middle East (AfME) Cardiovascular Epidemiological (ACE) study sub-analysis. Int Cardiovasc Forum J. 2017;11:6–12.

Article  Google Scholar 

Verma S, Alamuddin N, Alawadi F, et al. Prevalence of diabetes and cardiovascular risk in the Middle East and Africa: primary results of the PACT-MEA study. Circulation. 2023;147(16):1251–5.

Article  PubMed  PubMed Central  Google Scholar 

Schutte AE, Jafar TH, Poulter NR, et al. Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension. Cardiovasc Res. 2023;119(2):381–409.

Article  CAS  PubMed  Google Scholar 

Abboud M, Karam S. Hypertension in the Middle East: current state, human factors, and barriers to control. J Hum Hypertens. 2022;36(5):428–36.

Article  PubMed  Google Scholar 

NCD Risk Factor Collaboration. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–80.

Article  Google Scholar 

Abdelgadir E, Alsaeed M, Hafidh K, et al. Lipid control in patients with diabetes across primary and tertiary government health sectors in Dubai: a five-year pattern. Oman Med J. 2019;34(4):290–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al Rasadi K, Almahmeed W, AlHabib KF, et al. Dyslipidaemia in the Middle East: current status and a call for action. Atherosclerosis. 2016;252:182–7.

Article  CAS  PubMed  Google Scholar 

Al Sifri SN, Almahmeed W, Azar S, et al. Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment. PLoS ONE. 2014;9(1): e84350.

Article  PubMed  PubMed Central  Google Scholar 

Albackr HB, Al Waili K, Almahmeed W, et al. The Gulf Achievement of Cholesterol Targets in Out-Patients Study (GULF ACTION): design, rationale, and preliminary results. Curr Vasc Pharmacol. 2023;21(4):285–92.

Article  CAS  PubMed  Google Scholar 

Bhagavathula AS, Shah SM, Aburawi EH. Prevalence, awareness, treatment, and control of hypertension in the United Arab Emirates: a systematic review and meta-analysis. Int J Environ Res Public Health. 2021;18(23):12693.

Article  PubMed  PubMed Central  Google Scholar 

Ghader N, Al-Yateem N, Dalibalta S, et al. Cardiovascular health research priorities in the United Arab Emirates. Front Public Health. 2023;11:1130716.

Article  PubMed  PubMed Central  Google Scholar 

Khunti K, Chen H, Cid-Ruzafa J, et al. Glycaemic control in patients with type 2 diabetes initiating second-line therapy: results from the global DISCOVER study programme. Diabetes Obes Metab. 2020;22(1):66–78.

Article  CAS  PubMed  Google Scholar 

Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–35.

Article  PubMed  Google Scholar 

Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.

Article  CAS  PubMed  Google Scholar 

Usherwood T. Therapeutic inertia. Aust Prescr. 2024;47(1):15–9.

Article  PubMed  PubMed Central  Google Scholar 

Al-Sayyad AS, Alshehabi FM, Alabd DH, Marzooq AA. Medication adherence among patients with chronic diseases in primary health care centers in Bahrain. J Bahrain Med Soc. 2020;32(3):9–17.

Google Scholar 

Jabbar A, Abdallah K, Hassoun A, et al. Patterns and trends in insulin initiation and intensification among patients with type 2 diabetes mellitus in the Middle East and North Africa region. Diabetes Res Clin Pract. 2019;149:18–26.

Article  CAS  PubMed  Google Scholar 

Parati G, Goncalves A, Soergel D, et al. New perspectives for hypertension management: progress in methodological and technological developments. Eur J Prev Cardiol. 2023;30(1):48–60.

Article  PubMed  Google Scholar 

Yan X, Mudiganti S, Husby H, Hudnut A, Gbotoe M, Jones JB. Medication non-adherence and therapeutic inertia independently contribute to poor disease control for cardiometabolic diseases. Sci Rep. 2022;12(1):18936.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705.

Article  PubMed  PubMed Central  Google Scholar 

Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940–8.

Article  CAS  PubMed  Google Scholar 

Khunti K, Seidu S, Kunutsor S, Davies M. Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysis. Diabetes Care. 2017;40(11):1588–96.

Article  PubMed  Google Scholar 

McClellan M, Brown N, Califf RM, Warner JJ. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2019;139(9):e44-54.

Article  PubMed  Google Scholar 

Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on Hypertension. Lancet. 2016;388(10060):2665–712.

Article  PubMed  Google Scholar 

Böhm M, Schumacher H, Laufs U, et al. Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J. 2013;166(2):306–14.